{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.27","upperLimit":"24.99","value":"14.86"},{"groupId":"OG001","lowerLimit":"4.50","upperLimit":"15.19","value":"6.28"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG002","lowerLimit":"1.58","upperLimit":"NA","value":"14.70"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG003","lowerLimit":"2.17","upperLimit":"NA","value":"12.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Progression-free survival is defined as the time from first dose to the first documented progressive disease (PD), relapse, or death due to any cause during or after the treatment period, whichever occurred first, according to IWG 2006 response criteria for MDS. Participants who were still alive and progression-free were censored at the date of their last response assessment. Progressive disease is defined as follows: - an increase in BM blasts relative to nadir: •If nadir less than 5% blasts: ≥ 50% increase in blasts to \\> 5% blasts •If nadir 5% - 10% blasts: ≥ 50% increase in blasts to \\> 10% blasts •If nadir 10% - 20% blasts: ≥ 50% increase in blasts to \\> 20% blasts •If nadir 20% - 30% blasts: ≥ 50% increase in blasts to \\> 30% blasts And any of the following: •At least 50% decrement from maximum remission/response levels in granulocytes or platelets •Reduction in Hgb concentration by ≥ 2 g/dL •Transfusion dependence","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were given oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG000","title":"Stable Disease (SD) Cohort: Oral Azacitidine"},{"description":"Participants were given oral azacitidine 100 mg, 150mg, or 200mg tablets BID on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG001","title":"Progressive Disease (PD) Cohort: Oral Azacitidine"},{"description":"Participants received 100 mg oral azacitidine (AZA) tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab (Durva) 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG002","title":"Stable Disease Cohort: Oral Azacitidine and Durvalumab"},{"description":"Participants received 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG003","title":"Progressive Disease Cohort: Oral Azacitidine and Durvalumab"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all enrolled participants who received at least one dose of IP.","reportingStatus":"POSTED","timeFrame":"From first dose to the first documented progressive disease (PD), relapse, or death due to any cause (Up to 91 months)","title":"Kaplan-Meier Estimate of Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}